A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
NCT ID: NCT00111670
Last Updated: 2016-11-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
291 participants
INTERVENTIONAL
2005-06-30
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
DPP-IV Inhibitor
Escalating doses po bid or qd
2
DPP-IV Inhibitor
Escalating doses po bid or qd
3
DPP-IV Inhibitor
Escalating doses po bid or qd
4
DPP-IV Inhibitor
Escalating doses po bid or qd
5
Placebo
po bid or qd
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DPP-IV Inhibitor
Escalating doses po bid or qd
Placebo
po bid or qd
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* type 2 diabetes diagnosed \>=1 month before screening;
* no previous treatment, or previous treatment with no more than 2 oral medications.
Exclusion Criteria
* type 2 diabetes treated with insulin or a PPAR gamma agonist during the 3 months before screening;
* patients who are pregnant, breastfeeding or not using a reliable contraceptive method.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Salinas, California, United States
Clearwater, Florida, United States
Hialeah, Florida, United States
Pembroke Pines, Florida, United States
Blue Ridge, Georgia, United States
Aurora, Illinois, United States
Elkton, Maryland, United States
Oxon Hill, Maryland, United States
Troy, Michigan, United States
Pahrump, Nevada, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Warminster, Pennsylvania, United States
Dallas, Texas, United States
Midland, Texas, United States
San Antonio, Texas, United States
Richmond, Virginia, United States
Virginia Beach, Virginia, United States
Rousse, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
San José, , Costa Rica
Tartu, , Estonia
Tartu, , Estonia
Ogre, , Latvia
Riga, , Latvia
Klaipėda, , Lithuania
Vilnius, , Lithuania
Chihuahua City, , Mexico
Guadalajara, , Mexico
Guadalajara, , Mexico
Mexico City, , Mexico
Mexico City, , Mexico
Monterrey, , Mexico
Pachuca, , Mexico
Ponce, , Puerto Rico
Bucharest, , Romania
Cluj-Napoca, , Romania
Ploieşti, , Romania
Târgu Mureş, , Romania
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BM18102
Identifier Type: -
Identifier Source: org_study_id